The progression of hypertensive heart disease

Circulation

Volumn 123, Issue 3, 2011, Pages 327-334

  Drazner, Mark H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B;

ARTICLE; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; DISEASE COURSE; ECHOCARDIOGRAPHY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE WALL; HUMAN; HYPERTENSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

DISEASE PROGRESSION; HEART FAILURE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; VENTRICULAR REMODELING;

EID: 79251556005     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.845792     Document Type: Article

References (96)

1. Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V, Fauad-Tarazi F, Horan MJ, Marcus M, Massie B, Pfeffer MA, Re RN, Roccella EJ, Savage D, Shub C. The heart in hypertension. N Engl J Med. 1992;327:998-1008.
2. Drazner MH. The transition from hypertrophy to failure: how certain are we? Circulation. 2005;112:936-938.
3. Dorn GW II, Robbins J, Sugden PH. Phenotyping hypertrophy: eschew obfuscation. Circ Res. 2003;92:1171-1175.
4. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension. 2000;35:580-586.
5. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-1463.
6. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
7. Post WS, Larson MG, Levy D. Impact of left ventricular structure on the incidence of hypertension: the Framingham Heart Study. Circulation. 1994;90:179-185. (Pubitemid 24203678)
8. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest. 2007;117:568-575.
9. Spinale FG. Myocardial matrix remodeling and the matrix metallopro-teinases: influence on cardiac form and function. Physiol Rev. 2007;87: 1285-1342.
10. Schwartzkopff B, Motz W, Frenzel H, Vogt M, Knauer S, Strauer BE. Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation. 1993;88: 993-1003.
11. Hill JA, Olson EN. Cardiac plasticity. N Engl J Med. 2008;358: 1370-1380.
12. Diez J, Frohlich ED. A translational approach to hypertensive heart disease. Hypertension. 2010;55:1-8.
13. Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, Mureddu G, Pede S, Maggioni AP, Lucci D, Reboldi G. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet. 2009; 374:525-533.
14. Kizer JR, Arnett DK, Bella JN, Paranicas M, Rao DC, Province MA, Oberman A, Kitzman DW, Hopkins PN, Liu JE, Devereux RB. Differences in left ventricular structure between black and white hypertensive adults: the Hypertension Genetic Epidemiology Network study. Hypertension. 2004;43:1182-1188.
15. Drazner MH, Dries DL, Peshock RM, Cooper RS, Klassen C, Kazi F, Willett D, Victor RG. Left ventricular hypertrophy is more prevalent in blacks than whites in the general population: the Dallas Heart Study. Hypertension. 2005;46:124-129.
16. Sharp A, Tapp R, Francis DP, Mc GTSA, Hughes AD, Stanton AV, Zambanini A, Chaturvedi N, Byrd S, Poulter NR, Sever PS, Mayet J. Ethnicity and left ventricular diastolic function in hypertension: an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy. J Am Coll Cardiol. 2008;52:1015-1021.
17. Devereux RB, Roman MJ, de Simone G, O'Grady MJ, Paranicas M, Yeh JL, Fabsitz RR, Howard BV. Relations of left ventricular mass to demographic and hemodynamic variables in American Indians: the Strong Heart Study. Circulation. 1997;96:1416-1423.
18. Heckbert SR, Post W, Pearson GD, Arnett DK, Gomes AS, Jerosch-Herold M, Hundley WG, Lima JA, Bluemke DA. Traditional cardiovascular risk factors in relation to left ventricular mass, volume, and systolic function by cardiac magnetic resonance imaging: the Multiethnic Study of Atherosclerosis. J Am Coll Cardiol. 2006;48:2285-2292.
19. Post WS, Larson MG, Myers RH, Galderisi M, Levy D. Heritability of left ventricular mass: the Framingham Heart Study. Hypertension. 1997; 30:1025-1028.
20. Arnett DK, Hong Y, Bella JN, Oberman A, Kitzman DW, Hopkins PN, Rao DC, Devereux RB. Sibling correlation of left ventricular mass and geometry in hypertensive African Americans and whites: the HyperGEN study. Am J Hypertens. 2001;14:1226-1230.
21. Kapuku GK, Ge D, Vemulapalli S, Harshfield GA, Treiber FA, Snieder H. Change of genetic determinants of left ventricular structure in adolescence: longitudinal evidence from the Georgia Cardiovascular Twin Study. Am J Hypertens. 2008;21:799-805.
22. Rame JE, Drazner MH, Post W, Peshock R, Lima J, Cooper RS, Dries DL. Corin I555(P568) allele is associated with enhanced cardiac hyper-trophic response to increased systemic afterload. Hypertension. 2007;49: 857-864.
23. Petretto E, Sarwar R, Grieve I, Lu H, Kumaran MK, Muckett PJ, Mangion J, Schroen B, Benson M, Punjabi PP, Prasad SK, Pennell DJ, Kiesewetter C, Tasheva ES, Corpuz LM, Webb MD, Conrad GW, Kurtz TW, Kren V, Fischer J, Hubner N, Pinto YM, Pravenec M, Aitman TJ, Cook SA. Integrated genomic approaches implicate osteoglycin (Ogn) in the regulation of left ventricular mass. Nat Genet. 2008;40:546-552.
24. Vasan RS, Glazer NL, Felix JF, Lieb W, Wild PS, Felix SB, Watzinger N, Larson MG, Smith NL, Dehghan A, Grosshennig A, Schillert A, Teumer A, Schmidt R, Kathiresan S, Lumley T, Aulchenko YS, Konig IR, Zeller T, Homuth G, Struchalin M, Aragam J, Bis JC, Rivadeneira F, Erdmann J, Schnabel RB, Dorr M, Zweiker R, Lind L, Rodeheffer RJ, Greiser KH, Levy D, Haritunians T, Deckers JW, Stritzke J, Lackner KJ, Volker U, Ingelsson E, Kullo I, Haerting J, O'Donnell CJ, Heckbert SR, Stricker BH, Ziegler A, Reffelmann T, Redfield MM, Werdan K, Mitchell GF, Rice K, Arnett DK, Hofman A, Gottdiener JS, Uitterlinden AG, Meitinger T, Blettner M, Friedrich N, Wang TJ, Psaty BM, Van Duijn CM, Wichmann HE, Munzel TF, Kroemer HK, Benjamin EJ, Rotter JI, Witteman JC, Schunkert H, Schmidt H, Volzke H, Blankenberg S. Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. JAMA. 2009; 302:168-178.
25. Frazer KA, Murray SS, Schork NJ, Topol EJ. Human genetic variation and its contribution to complex traits. Nat Rev Genet. 2009;10:241-251.
26. Sehgal S, Drazner MH. Left ventricular geometry: does shape matter? Am Heart J. 2007;153:153-155.
27. Khouri MG, Peshock RM, Ayers CR, de Lemos JA, Drazner MH. A 4-tiered classification of left ventricular hypertrophy based on left ventricular geometry: the Dallas Heart Study. Circ Cardiovasc Imaging. 2010;3:164-171.
28. Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, Vargiu P, Simongini I, Laragh JH. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol. 1992;19:1550-1558.
29. De Simone G, Daniels SR, Kimball TR, Roman MJ, Romano C, Chinali M, Galderisi M, Devereux RB. Evaluation of concentric left ventricular geometry in humans: evidence for age-related systematic underestimation. Hypertension. 2005;45:64-68.
30. Ganau A, Devereux RB, Pickering TG, Roman MJ, Schnall PL, Santucci S, Spitzer MC, Laragh JH. Relation of left ventricular hemodynamic load and contractile performance to left ventricular mass in hypertension. Circulation. 1990;81:25-36.
31. Devereux RB, de Simone G, Ganau A, Roman MJ. Left ventricular hypertrophy and geometric remodeling in hypertension: stimuli, functional consequences and prognostic implications. J Hypertens Suppl. 1994;12:S117-S127.
32. Ross J Jr. On variations in the cardiac hypertrophic response to pressure overload. Circulation. 1997;95:1349-1351.
33. Fagard RH, Staessen JA, Thijs L. Prediction of cardiac structure and function by repeated clinic and ambulatory blood pressure. Hypertension. 1997;29:22-29.
34. Devereux RB, James GD, Pickering TG. What is normal blood pressure? Comparison of ambulatory pressure level and variability in patients with normal or abnormal left ventricular geometry. Am J Hypertens. 1993;6: 211S-215S.
35. Drazner MH. Left ventricular hypertrophy in special populations. In: Walsh RA, ed. Molecular Mechanisms of Cardiac Hypertrophy and Failure. Abingdon, United Kingdom: Taylor & Francis; 2005:501-512.
36. Krumholz HM, Larson M, Levy D. Sex differences in cardiac adaptation to isolated systolic hypertension. Am J Cardiol. 1993;72:310-313.
37. Chahal NS, Lim TK, Jain P, Chambers JC, Kooner JS, Senior R. New insights into the relationship of left ventricular geometry and left ventricular mass with cardiac function: a population study of hypertensive subjects. Eur Heart J. 2010;31:588-594.
38. Cheng S, Fernandes VR, Bluemke DA, McClelland RL, Kronmal RA, Lima JA. Age-related left ventricular remodeling and associated risk for cardiovascular outcomes: the Multi-Ethnic Study of Atherosclerosis. Circ Cardiovasc Imaging. 2009;2:191-198.
39. Zabalgoitia M, Berning J, Koren MJ, Stoylen A, Nieminen MS, Dahlof B, Devereux RB. Impact of coronary artery disease on left ventricular systolic function and geometry in hypertensive patients with left ventricular hypertrophy (the LIFE study). Am J Cardiol. 2001;88:646-650. (Pubitemid 32831098)
40. Palmieri V, Bella JN, Arnett DK, Liu JE, Oberman A, Schuck MY, Kitzman DW, Hopkins PN, Morgan D, Rao DC, Devereux RB. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) study. Circulation. 2001;103:102-107.
41. Gottdiener JS, Reda DJ, Materson BJ, Massie BM, Notargiacomo A, Hamburger RJ, Williams DW, Henderson WG; the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Importance of obesity, race and age to the cardiac structural and functional effects of hypertension. J Am Coll Cardiol. 1994;24:1492-1498.
42. De Simone G, Devereux RB, Roman MJ, Alderman MH, Laragh JH. Relation of obesity and gender to left ventricular hypertrophy in normo-tensive and hypertensive adults. Hypertension. 1994;23:600-606.
43. Markus MR, Stritzke J, Wellmann J, Duderstadt S, Siewert U, Lieb W, Luchner A, Doring A, Keil U, Schunkert H, Hense HW. Implications of prevalent and incident diabetes mellitus on left ventricular geometry and function in the ageing heart: the MONICA/KORA Augsburg cohort study. Nutr Metab Cardiovasc Dis. Published online before print November 25, 2009. doi:10.1016/j.numecd.2009.09. 005. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19939647. Accessed December 23, 2010.
44. Avelar E, Cloward TV, Walker JM, Farney RJ, Strong M, Pendleton RC, Segerson N, Adams TD, Gress RE, Hunt SC, Litwin SE. Left ventricular hypertrophy in severe obesity: interactions among blood pressure, nocturnal hypoxemia, and body mass. Hypertension. 2007;49:34-39.
45. Alderman MH, Cohen HW, Sealey JE, Laragh JH. Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens. 2004;17:1-7.
46. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, Buhler FR. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med. 1972;286:441-449.
47. Davila DF, Donis JH, Odreman R, Gonzalez M, Landaeta A. Patterns of left ventricular hypertrophy in essential hypertension: should echocardi-ography guide the pharmacological treatment? Int J Cardiol. 2008;124: 134-138.
48. Du Cailar G, Pasquie JL, Ribstein J, Mimran A. Left ventricular adaptation to hypertension and plasma renin activity. J Hum Hypertens. 2000;14:181-188.
49. Muscholl MW, Schunkert H, Muders F, Elsner D, Kuch B, Hense HW, Riegger GA. Neurohormonal activity and left ventricular geometry in patients with essential arterial hypertension. Am Heart J. 1998;135: 58-66.
50. Nakahara T, Takata Y, Hirayama Y, Asano K, Adachi H, Shiokawa G, Sumi T, Ogawa T, Yamashina A. Left ventricular hypertrophy and geometry in untreated essential hypertension is associated with blood levels of aldosterone and procollagen type III amino-terminal peptide. Circ J. 2007;71:716-721.
51. Olsen MH, Wachtell K, Hermann KL, Frandsen E, Dige-Petersen H, Rokkedal J, Devereux RB, Ibsen H. Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Am Heart J. 2002;144:530-537.
52. Velagaleti RS, Gona P, Levy D, Aragam J, Larson MG, Tofler GH, Lieb W, Wang TJ, Benjamin EJ, Vasan RS. Relations of biomarkers representing distinct biological pathways to left ventricular geometry. Circulation. 2008; 118:2252-2258.
53. Lopez B, Gonzalez A, Querejeta R, Larman M, Diez J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol. 2006;48:89-96.
54. Tang W, Devereux RB, Li N, Oberman A, Kitzman DW, Rao DC, Hopkins PN, Claas SA, Arnett DK. Identification of a pleiotropic locus on chromosome 7q for a composite left ventricular wall thickness factor and body mass index: the HyperGEN Study. BMC Med Genet. 2009;10:40.
55. Koide M, Nagatsu M, Zile MR, Hamawaki M, Swindle MM, Keech G, DeFreyte G, Tagawa H, Cooper Gt, Carabello BA. Premorbid determinants of left ventricular dysfunction in a novel model of gradually induced pressure overload in the adult canine. Circulation. 1997;95: 1601-1610.
56. Norton GR, Woodiwiss AJ, Gaasch WH, Mela T, Chung ES, Aurigemma GP, Meyer TE. Heart failure in pressure overload hypertrophy: the relative roles of ventricular remodeling and myocardial dysfunction. J Am Coll Cardiol. 2002;39:664-671.
57. Barrick CJ, Rojas M, Schoonhoven R, Smyth SS, Threadgill DW. Cardiac response to pressure overload in 129S1/SvImJ and C57BL/6J mice: temporal- and background-dependent development of concentric left ventricular hypertrophy. Am J Physiol. 2007;292:H2119-H2130.
58. Diwan A, Wansapura J, Syed FM, Matkovich SJ, Lorenz JN, Dorn GW II. Nix-mediated apoptosis links myocardial fibrosis, cardiac remodeling, and hypertrophy decompensation. Circulation. 2008;117:396-404.
59. Van Rooij E, Olson EN. Searching for miR-acles in cardiac fibrosis. Circ Res. 2009;104:138-140.
60. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41-46.
61. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papa-demetriou V, Rokkedal J, Harris K, Aurup P, Dahlof B. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004;292:2350-2356.
62. Meerson FZ. Compensatory hyperfunction of the heart and cardiac insufficiency. Circ Res. 1962;10:250-258.
63. Sasayama S, Ross J Jr, Franklin D, Bloor CM, Bishop S, Dilley RB. Adaptations of the left ventricle to chronic pressure overload. Circ Res. 1976;38:172-178.
64. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest. 1975;56:56-64.
65. Esposito G, Rapacciuolo A, Naga Prasad SV, Takaoka H, Thomas SA, Koch WJ, Rockman HA. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation. 2002;105:85-92.
66. Hill JA, Karimi M, Kutschke W, Davisson RL, Zimmerman K, Wang Z, Kerber RE, Weiss RM. Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation. 2000;101: 2863-2869.
67. Hill JA, Rothermel B, Yoo KD, Cabuay B, Demetroulis E, Weiss RM, Kutschke W, Bassel-Duby R, Williams RS. Targeted inhibition of cal-cineurin in pressure-overload cardiac hypertrophy: preservation of systolic function. J Biol Chem. 2002;277:10251-10255.
68. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation. 2004;109:1580-1589.
69. Pfeffer JM, Pfeffer MA, Mirsky I, Braunwald E. Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat. Proc Natl Acad Sci USA. 1982;79:3310-3314.
70. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93:215-228. (Pubitemid 28180855)
71. Haider AW, Larson MG, Franklin SS, Levy D. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med. 2003;138:10-16.
72. Rapaport E. Natural history of aortic and mitral valve disease. Am J Cardiol. 1975;35:221-227.
73. Spirito P, Maron BJ, Bonow RO, Epstein SE. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol. 1987;60: 123-129.
74. Carabello BA. Evolution of the study of left ventricular function: everything old is new again. Circulation. 2002;105:2701-2703.
75. Aurigemma GP, Silver KH, Priest MA, Gaasch WH. Geometric changes allow normal ejection fraction despite depressed myocardial shortening in hypertensive left ventricular hypertrophy. J Am Coll Cardiol. 1995;26: 195-202.
76. Rosen BD, Edvardsen T, Lai S, Castillo E, Pan L, Jerosch-Herold M, Sinha S, Kronmal R, Arnett D, Crouse JR III, Heckbert SR, Bluemke DA, Lima JA. Left ventricular concentric remodeling is associated with decreased global and regional systolic function: the Multi-Ethnic Study of Atherosclerosis. Circulation. 2005;112:984-991.
77. Shimizu G, Hirota Y, Kita Y, Kawamura K, Saito T, Gaasch WH. Left ventricular midwall mechanics in systemic arterial hypertension: myocardial function is depressed in pressure-overload hypertrophy. Circulation. 1991; 83:1676-1684.
78. Berenji K, Drazner MH, Rothermel BA, Hill JA. Does load-induced ventricular hypertrophy progress to systolic heart failure? Am J Physiol. 2005;289:H8-H16.
79. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Left ventricular mass and incidence of coronary heart disease in an elderly cohort: the Framingham Heart Study. Ann Intern Med. 1989;110:101-107.
80. Mehta SK, Rame JE, Khera A, Murphy SA, Canham RM, Peshock RM, de Lemos JA, Drazner MH. Left ventricular hypertrophy, subclinical atherosclerosis, and inflammation. Hypertension. 2007;49:1385-1391.
81. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation. 2001;104:1477-1482.
82. Rame JE, Ramilo M, Spencer N, Blewett C, Mehta SK, Dries DL, Drazner MH. Development of a depressed left ventricular ejection fraction in patients with left ventricular hypertrophy and a normal ejection fraction. Am J Cardiol. 2004;93:234-237.
83. Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, Manolio TA, Dries DL, Siscovick DS. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol. 2004;43:2207-2215.
84. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure: a clinical mechanistic overview. Arch Intern Med. 1996;156: 1789-1796.
85. Yancy CW. Heart failure in African Americans: pathophysiology and treatment. J Card Fail. 2003;9:S210-S215.
86. Bibbins-Domingo K, Pletcher MJ, Lin F, Vittinghoff E, Gardin JM, Arynchyn A, Lewis CE, Williams OD, Hulley SB. Racial differences in incident heart failure among young adults. N Engl J Med. 2009;360: 1179-1190.
87. Drazner MH. Racial differences in heart failure. N Engl J Med. 2009; 361:92; author reply 92.
88. Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, Meverden RA, Roger VL. Systolic and diastolic heart failure in the community. JAMA. 2006;296:2209-2216.
89. Goldberg LR, Jessup M. Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction. Circulation. 2006;113: 2851-2860.
90. Shapiro BP, Owan TE, Mohammed S, Kruger M, Linke WA, Burnett JC Jr, Redfield MM. Mineralocorticoid signaling in transition to heart failure with normal ejection fraction. Hypertension. 2008;51:289-295.
91. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR. Matrix metallopro-teinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006;113:2089-2096.
92. Martos R, Baugh J, Ledwidge M, O'Loughlin C, Murphy NF, Conlon C, Patle A, Donnelly SC, McDonald K. Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. Eur J Heart Fail. 2009;11:191-197.
93. Zile MR, Bennett TD, St John Sutton M, Cho YK, Adamson PB, Aaron MF, Aranda JM Jr, Abraham WT, Smart FW, Stevenson LW, Kueffer FJ, Bourge RC. Transition from chronic compensated to acute decom-pensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation. 2008;118: 1433-1441.
94. Melenovsky V, Borlaug BA, Rosen B, Hay I, Ferruci L, Morell CH, Lakatta EG, Najjar SS, Kass DA. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol. 2007;49:198-207.
95. Lam CS, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, Kass DA, Redfield MM. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation. 2007;115:1982-1990.
96. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009;53: 1119-1126.